In the context of prostate cancer and specifically in castration‐resistant prostate cancer (CRPC), changes in CD53 expression following PD‐L1 knockdown may reflect alterations in the balance of immune cell interactions and signaling cascades that contribute to tumor progression or resistance to therapy. This evidence concerns the gene CD53 and prostate cancer.